Application of Chrdl1 in preparation of medicine for treating and delaying glomerular basement membrane nephritis

By reducing Chrdl1 expression or protein activity, the BMP-SMAD signaling pathway is activated, and the treatment problem of anti-glomerular basal membranous nephritis is solved, which significantly improves renal function and structure, and provides a new treatment method.

CN118976109APending Publication Date: 2024-11-19BINZHOU MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411049157.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art does not clarify the role of Chrdl1 in anti-glomerular basal membranous nephritis and whether it improves disease progression by activating the BMP-SMAD signaling pathway, resulting in treatment difficulties.

Method used

Design and construct a mouse model for knocking down the Chrdl1 gene, using AAV9-shChrdl1 virus particles to reduce Chrdl1 expression or protein activity, and by activating the BMP-SMAD signaling pathway, research and application for the treatment and delay of anti-glomerular basal membranous nephritis.

Benefits of technology

It significantly improves renal injury and glomerulosclerosis, reduces urinary protein and creatinine levels, improves renal function, and has no side effects, providing a new targeted treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976109A_ABST
    Figure CN118976109A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and discloses an application of Chrdl1 in preparation of a medicine for treating and delaying anti-glomerular basement membrane nephritis, and a method comprises the following steps: designing and constructing a mouse model for knocking down a Chrdl1 gene, and researching the relationship between the Chrdl1 and the occurrence and development of the anti-glomerular basement membrane nephritis. Experimental results show that knock-down of the Chrdl1 gene can significantly reduce renal injury indexes, delay renal injury development and reduce inflammatory response and proteinuria level. Therefore, the knock-down Chrdl1 has protection and improvement effects on the occurrence and development of the glomerular basement membrane nephritis. Research finds that the clinical pathological characteristics of kidney injury can be remarkably improved by reducing the expression of Chrdl1, side effects are avoided, the treatment effect is remarkable, complications are avoided, and the clinical symptoms of the glomerular basement membrane nephritis can be fundamentally improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to but is not limited to the field of biomedical technology, and in particular relates to an application of Chrdl1 in preparing a drug for treating and delaying glomerular basement membrane nephritis. Background Art

[0002] Anti-glomerular basement membrane (GBM) nephritis is an autoimmune glomerulonephritis mediated by anti-GBM antibodies. It is characterized by rapidly progressive glomerulonephritis. Most cases have an acute onset, rapid progression, and poor prognosis. The mortality rate of untreated patients is as high as 75-90%. The prominent pathological manifestations are the formation of a large number of crescents in the glomeruli and the rupture of the Bowman's capsule wall. The degree of interstitial inflammation and fibrosis is parallel to the severity of glomerular lesions and directly affects the patient's prognosis. In recent years, with the continuous improvement of diagnostic capabilities, the number of cases of anti-GBM nephritis has been increasing year by year. This disease often causes severe renal damage. If not treated, it will rapidly progress to end-stage kidney disease (ESKD).

[0003] Chordin like-1 (Chrdl1) is an antagonist of the BMP-SMAD signaling pathway, which can block the activity of the bonemorphogenetic protein (BMP) system. Abnormal inhibition of BMP signaling plays a crucial role in the pathogenesis of renal fibrosis, and stimulation of BMP signaling can promote the production of phosphorylated SMADs (pSMAD) and is associated with anti-fibrotic effects. By inhibiting the expression of Chrdl1, the BMP-SMAD signaling pathway is activated in renal disease states. When BMP ligands bind and activate the receptor complex on the cell membrane surface, the signal is further transmitted to the cell interior through SMAD1 / 5 / 9 proteins in the classical BMP signaling transduction. After being phosphorylated, SMAD proteins are transferred from the cytoplasm to the nucleus, and then recruit tissue-specific transcription factors, thereby increasing the expression of pSMAD's direct downstream target genes (Id genes) and driving the expression of BMP gene targets.

[0004] Through the above analysis, the problems and defects of the prior art are as follows:

[0005] It remains unclear whether Chrdl1 is involved in the occurrence and development of anti-GBM nephritis and whether it can improve the disease progression of anti-GBM nephritis by activating the BMP-SMAD signaling pathway. Summary of the invention

[0006] In view of the problems existing in the prior art, the present invention provides an application of Chrdl1 in preparing a drug for treating and delaying glomerular basement membrane nephritis.

[0007] The present invention is achieved by using Chrdl1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis, the method comprising the following steps:

[0008] By designing and constructing a mouse model with Chrdl1 knockdown, the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis was studied.

[0009] Furthermore, the mouse model simulates the condition of Chrdl1 deficiency, which is helpful to observe and analyze the function of Chrdl1 in anti-glomerular basement membrane nephritis.

[0010] Furthermore, the drug is a Chrdl1 knockdown virus particle adeno-associated virus serotype9-short hairpin Chrdl1 (AAV9-shChrdl1).

[0011] Furthermore, the administration method of the Chrdl1 knockdown virus particle AAV9-shChrdl1 is intravascular injection, intramuscular injection, in situ tissue injection and oral administration.

[0012] Furthermore, the drug is a drug that reduces the expression of Chrdl1 gene and / or Chrdl1 protein.

[0013] Furthermore, the drug is a drug that reduces the activity of Chrdl1 protein.

[0014] Another object of the present invention is to provide a method for studying the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis, the method comprising the following steps:

[0015] (1) Wild-type mice were injected with AAV9-shScramble virus as a control group;

[0016] (2) wild-type mice were injected with AAV9-shChrdl1 virus as the experimental group to simulate the condition of reduced Chrdl1 expression;

[0017] (3) Establish an anti-GBM nephritis model in the above two groups of mice and monitor the course of the disease;

[0018] (4) Analyze the performance of the Chrdl1 knockdown mouse model during the development of anti-GBM nephritis to study the relationship between Chrdl1 and anti-GBM nephritis.

[0019] Another object of the present invention is to provide a drug for treating and delaying anti-glomerular basement membrane nephritis, the drug comprising Chrdl1 knockdown virus particles AAV9-shChrdl1, and its working principle is:

[0020] (1) introducing AAV9-shChrdl1 virus particles containing the Chrdl1 gene into the patient's body by injection or other administration methods;

[0021] (2) AAV9-shChrdl1 viral particles selectively infect and integrate into kidney cells in patients;

[0022] (3) In kidney cells, AAV9-shChrdl1 inhibits the expression of the Chrdl1 gene, thereby reducing the level of Chrdl1 protein in kidney cells;

[0023] (4) Treat and delay anti-glomerular basement membrane nephritis through the biological effects of Chrdl1 protein, such as activating the BMP-SMAD signaling pathway, alleviating renal inflammatory response and improving renal function.

[0024] Another object of the present invention is to provide a method for using a drug for treating and delaying glomerular basement membrane nephritis, the method comprising the following steps:

[0025] (1) Wild-type mice were used as the control group, and a mouse model with Chrdl1 gene knockdown was constructed as the experimental group;

[0026] (2) Establish anti-GBM nephritis models in two groups of mice and monitor the course of the disease;

[0027] (3) For the mouse model with knockdown of Chrdl1 gene, the Chrdl1 knockdown virus particles AAV9-shChrdl1 were administered by intravascular injection or intramuscular injection. The dosage and frequency of administration were determined according to the experimental design and mouse weight.

[0028] (4) Regularly test the renal function indicators of mice, such as urine protein (Albumin), urine creatinine (Creatinine), etc., and perform histopathological examination to evaluate the changes in renal structure and function;

[0029] (5) The experimental results were statistically analyzed and the differences in renal function, histopathology, etc. between the two groups of mice were compared to evaluate the therapeutic effect of knocking down Chrdl1 against glomerular basement membrane nephritis.

[0030] Another object of the present invention is to provide a method for using the drug for treating anti-glomerular basement membrane nephritis, the method comprising the following steps:

[0031] (1) Use an established mouse model of renal injury as the experimental group;

[0032] (2) Giving the experimental group mice a Chrdl1 inhibitor that can reduce Chrdl1 gene expression or Chrdl1 protein activity, with oral administration or in situ tissue injection. The dosage and frequency of administration are determined according to the experimental design and mouse weight;

[0033] (3) Regularly test the renal function indicators of mice and perform histopathological examinations to evaluate changes in renal structure and function;

[0034] (4) Statistically analyze the experimental results and compare the differences in renal function, histopathology, etc. between mice before and after administration to evaluate the therapeutic effect of Chrdl1 inhibitors against glomerular basement membrane nephritis and consider its side effects and safety issues.

[0035] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0036] First, the present invention adopts the following technical solutions:

[0037] By designing and constructing a mouse model with knockdown of the Chrdl1 gene, the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis was studied. The experimental results showed that:

[0038] (1) The renal function indicators creatinine and urine protein were significantly reduced;

[0039] (2) Histological examination showed that histological damage and inflammatory cell infiltration were significantly improved in the Chrdl1 knockdown group compared with the control group.

[0040] It can be seen that knocking down Chrdl1 has a protective and improving effect on the occurrence and development of anti-GBM nephritis, and Chrdl1 has a new use in treating and delaying anti-GBM nephritis.

[0041] Through research, it was found that knocking down Chrdl1 can significantly improve renal damage and glomerular sclerosis caused by anti-GBM nephritis, without any side effects, significant therapeutic effect, and no complications. It can fundamentally improve the clinical symptoms of anti-GBM nephritis.

[0042] Second, the current treatment of anti-glomerular basement membrane disease is mainly:

[0043] 1. Intensive treatment during acute progressive phase:

[0044] (1) Enhanced plasma exchange or immunoadsorption: It can remove anti-GBM antibodies in the patient's circulation, and combined use of immunosuppressants can block the re-production of antibodies;

[0045] (2) Shock therapy: methylprednisolone or cyclophosphamide shock therapy is often used;

[0046] 2. Long-term maintenance treatment:

[0047] (1) Immunosuppressive therapy: hormones combined with immunosuppressants, the most commonly used immunosuppressants are cyclophosphamide and azathioprine;

[0048] (2) Anticoagulant therapy: Low molecular weight heparin is currently the most widely used, and warfarin can also be used for anticoagulation.

[0049] 3. Supportive and alternative treatment:

[0050] For patients whose renal function has entered the stage of failure or whose renal function has rapidly deteriorated due to ineffective treatment, dialysis treatment should be performed as soon as possible to maintain life and gain time for treatment.

[0051] Different from traditional treatment methods, the present invention uses adeno-associated virus as a vector to directly deliver the Chrdl1-shRNA gene to target cells, reducing the expression of CHRDL1 protein, thereby weakening its inhibitory effect on the BMP-SMAD pathway, causing the pathway to be significantly activated in the disease state, thereby exerting its role in protecting kidney damage and renal fibrosis.

[0052] Third, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:

[0053] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:

[0054] After clinical transformation, this program can provide a new treatment method for patients with anti-glomerular basement membrane nephritis, provide precise targeted treatment for kidney damage in the anti-GBM nephritis patient group, treat or delay kidney damage caused by nephritis, save medical resources, and reduce medical expenses.

[0055] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:

[0056] There are no reports on the therapeutic effect of Chrdl1 in anti-GBM nephritis. Therefore, this study clarifies the role of Chrdl1 in anti-GBM nephritis; the therapeutic effect of Chrdl1 in anti-GBM nephritis has not been studied yet, and this study fills this gap.

[0057] (3) The technical solution of the present invention solves the technical problems that people have been eager to solve but have never been able to solve successfully:

[0058] The application of Chrdl1 to improve anti-GBM nephritis has the following significant technical advances:

[0059] 1. Targeted delivery: This approach uses adeno-associated virus as a vector to directly deliver the Chrdl1 plasmid to the kidney.

[0060] 2. Target of Chrdl1: Chrdl1 is an effective target for improving anti-GBM nephritis. Chrdl1 knockdown plasmid DNA is preferentially delivered to kidney tissue through adeno-associated virus targeted delivery strategy, which can reduce the expression of Chrdl1 and thus exert its therapeutic effect against GBM nephritis.

[0061] 3. Regulation of gene expression: Chrdl1 knockdown plasmid DNA is delivered to renal podocytes via adeno-associated virus to achieve translation or expression and regulate downstream signaling pathways, thereby changing the pathological process of anti-GBM nephritis and achieving a therapeutic effect.

[0062] In general, through strategies such as targeted delivery and gene expression regulation of Chrdl1, precise treatment of anti-GBM nephritis was achieved with high therapeutic efficacy and biosafety, bringing significant technological progress to the field of anti-GBM nephritis treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 This is a graph showing changes in the gene level of Chrdl1 in the kidneys of mice resistant to glomerular basement membrane nephritis after knocking down Chrdl1;

[0064] Figure 2 The following are the pathological changes in renal tissue of mice with glomerular basement membrane nephritis after knockdown of Chrdl1: Periodic Acid-Schiff stain (PAS) and hematoxylin-eosin (HE) staining were used to analyze the changes in mouse glomerular morphology;

[0065] Figure 3 The ultrastructural changes of glomerular capillary loops in the kidney tissue of mice with anti-glomerular basement membrane nephritis after Chrdl1 knockdown were observed by transmission electron microscopy.

[0066] Figure 4 This is a graph showing changes in urine protein-creatinine ratio (ACR) of anti-glomerular basement membrane nephritis mice injected with nephrotoxic serum (NTS) on days 3, 5, 7, and 14 after Chrdl1 knockdown;

[0067] Figure 5 This is a graph showing the changes in the expression of NPHS2Stomatin Family Member (Podocin) and intermediate filament protein (Desmin) in the kidneys of mice resistant to glomerular basement membrane nephritis after Chrdl1 knockdown detected by immunofluorescence;

[0068] Figure 6The following are the expression changes of podocyte-related molecules and inflammatory factor markers in mice with glomerular basement membrane nephritis after Chrdl1 knockdown: (a) Real-time fluorescence quantitative PCR (qRT-PCR) detected the changes in the transcription levels of NPHS1 (NPHS1Adhesion Molecule, Nephrin), NPHS2 (NPHS2 Stomatin Family Member, Podocin), Mcp-1 (Monocyte chemoattractant protein-1), F4 / 80, and Interleukin-1beta (Il-1β) genes in the kidney; (b) qRT-PCR detection results of the transcription levels of pSMAD signaling pathway target genes Inhibitor Of DNA Binding 1 (Id1), Inhibitor Of DNA Binding 2 (Id2), Inhibitor Of DNA Binding 3 (Id3), and Inhibitor OfDNA Binding 4 (Id4) in mouse kidney. DETAILED DESCRIPTION

[0069] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0070] Anti-glomerular basement membrane nephritis has become a clinical problem that threatens human life and property. Its incidence and mortality rates are increasing year by year. If kidney damage is too severe or occurs repeatedly, it will enter a progressive and irreversible disease process, gradually developing and affecting the quality of life and even threatening the patient's life.

[0071] In recent years, studies have found that Chrdl1 is an antagonist of the BMP-SMAD signaling pathway, which can block the activity of the bonemorphogenetic protein (BMP) system. Abnormal inhibition of BMP signaling plays a crucial role in the pathogenesis of renal fibrosis, while stimulation of BMP signaling can promote the production of pSMAD and is associated with anti-fibrotic effects. Our results show that inhibiting the expression of Chrdl1 can promote the activation of BMP-SMAD signaling in the tubulointerstitium, thereby improving renal function.

[0072] 1. Model construction:

[0073] Mouse model with Chrdl1 knockdown: In order to study the effect of Chrdl1 deficiency on anti-GBM nephritis, scientists designed and constructed a mouse model with Chrdl1 knockdown. This model simulates the situation of Chrdl1 deficiency and helps to observe and analyze the function of Chrdl1 in anti-GBM nephritis.

[0074] 2. Study the relationship between Chrdl1 and anti-glomerular basement membrane nephritis:

[0075] By comparing the performance of knockdown and normal mouse models in the development of anti-GBM nephritis, scientists can further study the relationship between Chrdl1 and anti-GBM nephritis, including analyzing the role of Chrdl1 in the pathogenesis of anti-GBM nephritis.

[0076] The drug provided in the embodiment of the present invention is a Chrdl1 knockdown virus particle AAV9-shChrdl1. The working principle of this drug is as follows:

[0077] 1. Gene delivery: Chrdl1 knockdown virus particle AAV9-shChrdl1 has the ability to deliver the Chrdl1 gene to target cells. When AAV9-shChrdl1 is injected into the body, it can selectively infect and integrate into kidney cells.

[0078] 2. Gene expression: Once AAV9-shChrdl1 integrates into the genome of kidney cells, it can inhibit the expression of the Chrdl1 gene. This leads to a decrease in the level of CHRDL1 protein in kidney cells.

[0079] 3. Biological effects: Reduced CHRDL1 protein can exert biological effects through multiple pathways, thereby treating and delaying anti-glomerular basement membrane nephritis. For example, reducing the expression of CHRDL1 protein can weaken its inhibitory effect on the BMP-SMAD pathway, causing the pathway to be significantly activated in the disease state, thereby playing its role in improving glomerular damage and reducing proteinuria levels.

[0080] 4. Long-term treatment: Since AAV9-shChrdl1 can stably integrate into the genome of kidney cells, it can achieve long-term stable inhibition of CHRDL1 protein. This makes AAV9-shChrdl1 an anti-glomerular basement membrane nephritis therapeutic drug with long-term therapeutic effects.

[0081] The present invention designs and constructs a mouse model of knocking down the Chrdl1 gene, and deeply studies the relationship between Chrdl1 and anti-glomerular basement membrane nephritis. Based on these studies, it is proposed to use the Chrdl1 knockdown virus particle AAV9-shChrdl1 as a drug for treating and delaying anti-glomerular basement membrane nephritis. This drug exerts biological effects by reducing the expression of CHRDL1 protein in kidney cells, and has long-term therapeutic effects and good application prospects.

[0082] The embodiment of the present invention provides an application of Chrdl1 in preparing a drug for treating and delaying glomerular basement membrane nephritis, the method comprising the following steps:

[0083] By designing and constructing a mouse model with Chrdl1 knockdown, the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis was studied.

[0084] The mouse model simulates the condition of Chrdl1 deficiency, which is helpful to observe and analyze the function of Chrdl1 in anti-glomerular basement membrane nephritis.

[0085] The drug is the Chrdl1 knockdown viral particle AAV9-shChrdl1.

[0086] The administration method of the Chrdl1 knockdown virus particle AAV9-shChrdl1 is intravascular injection, intramuscular injection, in situ tissue injection and oral administration.

[0087] The drug is a drug that reduces the expression of Chrdl1 gene and / or Chrdl1 protein.

[0088] The drug is a drug that reduces the activity of the Chrdl1 protein.

[0089] The embodiment of the present invention provides a method for studying the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis, the method comprising the following steps:

[0090] (1) Wild-type mice were injected with AAV9-shscramble virus as a control group;

[0091] (2) wild-type mice were injected with AAV9-shChrdl1 virus as the experimental group to simulate the condition of reduced Chrdl1 expression;

[0092] (3) Establish an anti-GBM nephritis model in the above two groups of mice and monitor the course of the disease;

[0093] (4) Analyze the performance of the Chrdl1 knockdown mouse model during the development of anti-GBM nephritis to study the relationship between Chrdl1 and anti-GBM nephritis.

[0094] The embodiment of the present invention provides a drug for treating and delaying anti-glomerular basement membrane nephritis, the drug comprising Chrdl1 knockdown virus particles AAV9-shChrdl1, and its working principle is:

[0095] (1) introducing AAV9-shChrdl1 virus particles containing the Chrdl1 gene into the patient's body by injection or other administration methods;

[0096] (2) AAV9-shChrdl1 viral particles selectively infect and integrate into kidney cells in patients;

[0097] (3) In kidney cells, AAV9-shChrdl1 inhibits the expression of the Chrdl1 gene, thereby reducing the level of Chrdl1 protein in kidney cells;

[0098] (4) Treat and delay anti-glomerular basement membrane nephritis through the biological effects of Chrdl1 protein, such as activating the BMP-SMAD signaling pathway, alleviating renal inflammatory response and improving renal function.

[0099] Another object of the present invention is to provide a method for using a drug for treating and delaying glomerular basement membrane nephritis, characterized in that the method comprises the following steps:

[0100] (1) Wild-type mice were used as the control group, and a mouse model with Chrdl1 gene knockdown was constructed as the experimental group;

[0101] (2) Establish anti-GBM nephritis models in two groups of mice and monitor the course of the disease;

[0102] (3) For the mouse model with knockdown of Chrdl1 gene, the Chrdl1 knockdown virus particles AAV9-shChrdl1 were administered by intravascular injection or intramuscular injection. The dosage and frequency of administration were determined according to the experimental design and mouse weight.

[0103] (4) Regularly test the renal function indicators of mice, such as urine protein and urine creatinine, and perform histopathological examinations to evaluate changes in renal structure and function;

[0104] (5) The experimental results were statistically analyzed and the differences in renal function, histopathology, etc. between the two groups of mice were compared to evaluate the therapeutic effect of knocking down Chrdl1 against glomerular basement membrane nephritis.

[0105] The embodiment of the present invention provides a method for using a drug for treating anti-glomerular basement membrane nephritis, characterized in that the method comprises the following steps:

[0106] (1) Use an established mouse model of renal injury as the experimental group;

[0107] (2) Giving the experimental group mice a Chrdl1 inhibitor that can reduce Chrdl1 gene expression or Chrdl1 protein activity, with oral administration or in situ tissue injection. The dosage and frequency of administration are determined according to the experimental design and mouse weight;

[0108] (3) Regularly test the renal function indicators of mice and perform histopathological examinations to evaluate changes in renal structure and function;

[0109] (4) Statistically analyze the experimental results and compare the differences in renal function, histopathology, etc. between mice before and after administration to evaluate the therapeutic effect of Chrdl1 inhibitors against glomerular basement membrane nephritis and consider its side effects and safety issues.

[0110] The specific application fields or related products of the present invention.

[0111] By designing and constructing a mouse model with Chrdl1 knockdown, the relationship between Chrdl1 and the occurrence and development of anti-GBM nephritis was studied.

[0112] The drug provided in the embodiment of the present invention is the Chrdl1 knockdown virus particle AAV9-shChrdl1.

[0113] The administration method of the Chrdl1 knockdown virus particle AAV9-shChrdl1 provided in the embodiment of the present invention is intravascular injection, intramuscular injection, in situ tissue injection and oral administration.

[0114] The drug provided in the embodiment of the present invention is a drug for reducing the expression of Chrdl1 gene and / or CHRDL1 protein.

[0115] The drug provided in the embodiment of the present invention is a drug for reducing the activity of CHRDL1 protein.

[0116] Relevant evidence of the technical effects achieved by the embodiments of the present invention.

[0117] 1. Experimental methods

[0118] 1.1 Selection of experimental animals and feeding conditions

[0119] The selected 8-12 week old C57BL / 6 male mouse strain was purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. After the mice were purchased, they were kept in the SPF-level experimental animal breeding room of Binzhou Medical College Yantai Campus, using an IVC-type independent ventilation system, and were raised in cages. No more than 6 mice were kept in each cage. The temperature of the breeding environment was about 22°C, and the humidity was about 60%. They were given sufficient food and water, maintained day and night alternation, and the bedding was changed once a week. Drinking water, mouse cages and other items were sterilized with high-pressure steam before use. The frequency of personnel entering and leaving the breeding room was limited and the operating noise was minimized to reduce the stress response of the animals and interfere with the experimental conclusions.

[0120] 1.2 Construction of anti-glomerular basement membrane nephritis model

[0121] Twenty mice were randomly divided into two groups, 10 mice were injected with AAV9-shScramble virus as group A, and 10 mice were injected with AAV9-shChrdl1 virus as group B. Three weeks after the injection, the mice in groups A and B were injected with nephrotoxic serum (NTS) once through the tail vein. Urine and serum samples were collected on the 3rd, 5th, 7th, and 14th days after the injection to detect urine protein, blood creatinine, and blood urea nitrogen content, and kidney tissues were taken at the above time points to observe pathological changes.

[0122] 1.3 Chrdl1 knockdown virus particles AAV9-shChrdl1 was constructed using the following method

[0123] (I) Construction of plasmid

[0124] (1) Construction of Chrdl1 target gene

[0125] The target gene siRNA (small interfering RNA) sequence and shRNA (short hairpin RNA) sequence are as follows:

[0126] siRNA1 sequence: GCAAGTCATGCGAATACAA

[0127] shRNA1 sequence:

[0128] Top strand: AATTCGCAAGTCATGCGAATACAACTCGAGTTGTATTCGCATGACTTGCT TTTTTG;

[0129] Bottom strand: GATCCAAAAAAGCAAGTCATGCGAATACAACTCGAGTTGTATTCGCATGACTTGCG.

[0130] The design of the primers includes exchange pairing bases, Bacillus amyloliquefaciens HI (BamHI) restriction site, and Escherichia coli-RI (EcoRI) restriction site.

[0131] Total ribonucleic acid (RNA) was extracted from mouse tissues and reverse transcribed into complementary DNA (cDNA). The cDNA was used as a template for polymerase chain reaction (PCR) amplification (PCR cycle parameters: 95°C, 5 min, 1 cycle; then 95°C, 30 s, 55°C, 30 s, 72°C, 60 s, 30 cycles, 72°C, 10 min, one cycle again; and finally 4°C, ∞, one cycle). Then, the mouse Chrdl1 gene fragment was recovered by electrophoresis and gel cutting.

[0132] (2) Construction and extraction of recombinant plasmid

[0133] First, the pHBAAV-U6-MCS vector and the recovered mouse Chrdl1 gene fragment were double-digested with restriction endonucleases BamHI and EcoRI. The final digestion system was 50 μL, including: 10×CutSmart Buffer 5 μL, vector 10 μL, BamHI 1 μL, EcoRI 1 μL, and the remaining system was made up with double distilled water.

[0134] Next, the linearized vector DNA was mixed with the purified PCR product at a ratio of 1:2 (molar ratio), and the HBinfusionTM one-step cloning and ligation system was used. The reaction was carried out at 50°C for 30 minutes under the action of HB infusionTM Master mix, and then cooled in an ice water bath for 5 minutes before transformation. 10 μL of the above reaction product was added to 100 μL of DH5α competent cells, mixed and placed on ice for 30 minutes, then heat-shocked at 42°C for 90 seconds, and then incubated on ice for 3 minutes, and then 200 μL of LB medium was added, and shaken and cultured in a shaker at 37°C for 1 hour.

[0135] Finally, all the above bacterial liquid was evenly spread on a plate containing ampicillin antibiotics and incubated in an incubator for 12 hours.

[0136] (3) Identification of recombinant plasmids

[0137] Pick 5 single colonies from the plate and place them in 5 LB culture media containing ampicillin respectively. Shake the culture medium at 37°C. After 12 hours, take 1 mL of the culture medium from each culture medium and send it to Sangon Biotech Co., Ltd. for sequencing to identify the accuracy of the recombinant plasmid. The remaining culture medium is preserved with 30% glycerol and stored in a -80°C refrigerator for later use.

[0138] (II) AAV-293 cell culture

[0139] (1) Recovery of AAV-293 cells:

[0140] ① Set the water bath temperature to 37°C;

[0141] ② Take out the frozen AAV-293 cells from the liquid nitrogen tank, quickly put them into a water bath and shake them quickly, trying to completely dissolve the cell solution within 1 minute;

[0142] ③ Transfer the cell solution to a 15 mL centrifuge tube, add 5 mL of fresh complete medium to the centrifuge tube, mix well and centrifuge at 1000 rpm for 5 min;

[0143] ④ Remove the supernatant, add 5 mL of fresh complete culture medium, mix the precipitate and transfer it to a T225 culture flask, add Dulbecco's Modified Eagle's medium (DMEM) complete culture medium (DMEM + penicillin + streptomycin + 10% fetal bovine serum), and place the culture flask steadily in an incubator at 37°C and 5% CO2 for culture.

[0144] (2) The cells were digested with 0.25% trypsin for 5 min, then the trypsin was removed and fresh complete medium was added to mix thoroughly. The cells were then transferred to a 15 mL centrifuge tube and centrifuged at 1000 rpm for 5 min. The supernatant was discarded and 5 mL of complete medium was added to the precipitate for resuspending.

[0145] (3) Take 50 μL of the mixed cells and place them in a 1.5 mL EP tube. Add 450 μL of DMEM complete medium and mix well. Take 10 μL of cells and count them in a counting plate. Subculture the AAV-293 cells into a 100 mm culture dish (for transfection). The day of plating is recorded as the first day.

[0146] (4) Place the above culture dish in an incubator at 37°C and 5% CO2 and observe the cell density after two days of culture. When the culture dish reaches 80% to 90% full, transfection can be performed.

[0147] (III) AAV packaging and concentration

[0148] (1) Plasmid amplification

[0149] The constructed AAV vector, packaging plasmid and auxiliary plasmid (vector plasmid carrying the target gene, pAAV-RC, pHelper, respectively) were extracted in large quantities using the Qiagen large-scale extraction kit. When the concentration was greater than 1 μg / μL and A260 / 280 was between 1.7 and 1.8, they could be used to package the virus.

[0150] (2) The culture dish containing AAV-293 cells (the cells reach 80% to 90% monolayer confluence) is replaced with a culture medium, and then the cells are transfected using Lipofiter™ transfection reagent (purchased from Hanheng Biotechnology, for instructions, refer to the Lipofiter™ manual).

[0151] (3) LipofiterTM transfection reagent was mixed with DMEM medium without dual antibody and serum at a volume ratio of 1:25 (to obtain mixed solution 1), the above-mentioned AAV vector, packaging plasmid and auxiliary plasmid were mixed at a volume ratio of 1:2:1 (to obtain mixed solution 2), mixed solution 1 and mixed solution 2 were mixed at a volume ratio of 1:1, and added dropwise to the pre-plated AAV-293 cells, cultured at 37°C and 5% CO2, and replaced with DMEM complete medium after 6 hours, and the culture dish with the transfection plasmid was placed in an incubator and cultured for 72 hours.

[0152] (4) AAV virus collection: 72 h after transfection, cells were harvested from a 150 mm culture dish using a cell scraper and centrifuged at 150 g for 3 min to collect the cell pellet, which was then resuspended in 300 μL PBS. The centrifuge tube containing the cells was repeatedly frozen and thawed three times in liquid nitrogen and a 37°C water bath, followed by centrifugation at 2000 g for 5 min at 4°C to remove cell debris and collect the lysis supernatant containing AAV particles (crude virus extract).

[0153] (5) Purification of AAV:

[0154] ① Treatment with universal nuclease: Add 0.1 μL Benonase enzyme to every 1 mL of crude virus extract, incubate in a 37°C water bath for 1 hour to remove the cell genome and residual plasmid DNA in the crude virus extract, then centrifuge at 600 g for 10 minutes at 4°C and take the supernatant;

[0155] ② Column purification: AAV virus column purification was performed according to the Biomiga adeno-associated virus purification kit V1469-01 operating instructions;

[0156] ③ Centrifugation: Add the AAV virus sample liquid (4 mL) obtained by column purification into an ultrafiltration tube and centrifuge at 1400 g for 30 min to obtain the AAV virus (about 1 mL). Collect the purified AAV virus and store it at -80°C.

[0157] (6) AAV virus packaging titer determination (using qRT-PCR method):

[0158] Take 3μL AAV virus, add 10μL DNAse, 41μL high-pressure water and 6μL Dilution Buffer, mix well and place in a 37℃ water bath for 1h, then place in a metal bath and heat at 100℃ for 10min. After cooling naturally to room temperature, add 2μL proteinase K, place in a 55℃ water bath for 1h, then quickly place in a metal bath and heat at 100℃ for 10min. After cooling naturally to room temperature again, centrifuge to allow the liquid on the tube wall to gather at the bottom of the tube. After treatment, dilute 10 times and use it for qRT-PCR titer detection.

[0159] 1.4 Systemic delivery of AAV9-shChrdl1

[0160] AAV9-shChrdl1 was injected via the tail vein, and anti-glomerular basement membrane nephritis model was established 3 weeks after injection.

[0161] 1.5 Urine protein-creatinine ratio determination

[0162] Urine protein was detected according to the instructions of the enzyme-linked immunosorbent assay (ELISA) kit, and urine creatinine was detected according to the creatinine kit, and the urine protein / creatinine ratio (Albumin / Creatinine Ratio, ACR) was calculated.

[0163] 1.6 Histological staining

[0164] (I) Preparation of paraffin sections

[0165] (1) Renal tissue was fixed with PFA for 24 hours and then rinsed with tap water overnight.

[0166] (2) Tissue dehydration, transparency and wax impregnation:

[0167] Follow the steps below to filter in sequence: 1) 75% ethanol, overnight treatment; 2) 85% ethanol, 3 hours; 3) 95% ethanol I, 2 hours; 4) 95% ethanol I, 1 hour; 5) anhydrous ethanol I, 1 hour; 6) anhydrous ethanol II, 1 hour; 7) xylene I, 30 minutes; 8) xylene II, 30 minutes; 9) soft wax, 2 hours; 9) hard wax, 1 hour.

[0168] (3) Paraffin embedding and tissue sectioning: Place solid paraffin in an embedding machine and fully dissolve it. Place the tissue in a metal embedding box and pour the dissolved paraffin into the embedding box. Transfer the embedding box to a cooling table (start the machine 2 hours in advance for precooling) and let it solidify overnight. Take out the solidified wax block and slice it with a microtome. The slice thickness is 5 μm. Spread the slice with warm water and use a soft brush to pick up the slice and place it on a slide.

[0169] (4) Baking: Place the tissue on the slide in an oven at 60°C for 2 h.

[0170] (ii) PAS staining

[0171] The following steps were followed in order: 1) xylene I, 15 minutes; 2) xylene II, 15 minutes; 3) anhydrous ethanol I, 5 minutes; 4) anhydrous ethanol II, 5 minutes; 5) 95% ethanol I, 5 minutes; 6) 95% ethanol II, 5 minutes; 7) 85% ethanol, 5 minutes; 8) 75% ethanol, 5 minutes; 9) distilled water, 5 minutes; 10) Alcian blue, 10-20 seconds; 11) distilled water, 2 minutes; 12) oxidant, 5 minutes; 13) tap water, 1 minute; 14) Schiff Reagent, 10-20 minutes; 15) running water, 10 minutes; 16) hematoxylin, 1-2 minutes; 17) tap water, 2 minutes; 18) acid differentiation solution, 2-5 seconds; 19) tap water, 1 minute; 20) Scott blue anti-blue solution, 10 minutes; 21) tap water, 3 minutes; 22) 85% ethanol, 5 minutes; 23) 95% ethanol I, 5 minutes; 24) 95% ethanol II, 5 minutes; 25) anhydrous ethanol I, 5 minutes; 26) anhydrous ethanol II, 5 minutes; 27) xylene I, 5 minutes; 28) xylene II, 5 minutes. Seal the slides with neutral gum.

[0172] (III) After the PAS-stained sections were photographed with an optical microscope, the photos were analyzed using Image J software to calculate the percentage of mesangial matrix area to glomerular area (n = 4 per group, 5 fields of view per animal). At the same time, the glomerular sclerosis index (GSI) was calculated: the degree of glomerular sclerosis was divided into 4 levels: level 0: basically normal or glomerular sclerosis area <25%; level 1: ~50%; level 2: ~75%; level 3: >75%. The GSI, which represents the degree of glomerular sclerosis, was calculated based on the average sclerosis area of ​​each glomerulus, and the formula was: GSI = (1×n1+2×n2+3×n3) / total number of glomeruli per slice] × 100% (n represents the number of diseased glomeruli).

[0173] 1.7 Immunofluorescence (IF)

[0174] (1) Kidney frozen sections: Take out the optical coherence tomography (OCT)-embedded kidney tissue from a -80°C refrigerator and place it in a -20°C refrigerator for equilibration for 30 min-1 h. Precool the freezing section machine to -20°C in advance. Lower the temperature of the slicer head to -20°C before use. After trimming the tissue, adjust the section thickness to 5 μm (or 7 μm) and use a glass slide to pull and adhere the frozen section.

[0175] (2) Fixation: Place the slices in ice methanol and fix them in a -20°C refrigerator for 20 min.

[0176] (3) Blocking: Wash the fixed slices with phosphate-buffered saline (PBS) to remove the surrounding OCT. Use an immunohistochemistry pen to draw circles around the tissue to lock in moisture. Place the slices in a dark box and drop 60 μL of blocking solution (9 mL PBS + 1 mL Fetal bovine serum (FBS) + 20 μL Tween-20). Block at room temperature for 1 hour. Be careful not to dry the slices.

[0177] (4) Antibody incubation: Dilute the primary antibody with blocking solution according to the antibody instructions. Add no less than 50 μL of antibody diluent to each slice and incubate at 4°C overnight. After incubation, discard the primary antibody and wash the slides three times with 1× PBS, 10 min each time. Dilute the secondary antibody with blocking solution in a certain proportion and incubate at room temperature for 1.5-2 h. After incubation, wash the slides three times with 1× PBS, 10 min each time. After washing, add 50 μL DAPI (4',6-diamidino-2-phenylindole) to stain the nucleus, incubate at room temperature for 5 min, and wash the slides three times with 1× PBS, 10 min each time. Keep away from light after incubation with secondary antibody.

[0178] (5) Sealing with sealing agent and taking pictures: Use pre-prepared Mowiol sealing agent, image with laser confocal microscopy, and analyze the results.

[0179] 1.8 Real-time quantitative PCR (qRT-PCR)

[0180] The extracted glomeruli were homogenized in Trizol (Ambion, USA) to obtain total RNA. According to the instructions provided by the manufacturer (Takara, Japan), the RNA was reverse transcribed using a reverse transcription system kit, and then fluorescent quantitative PCR was performed using a ThermoFisher QS3 PCR instrument according to the instructions in the SYBR Green PCR Master Mix (ABI, USA) kit. The internal reference gene was β-actin, and the relative expression level of each target gene mRNA was calculated based on ΔCT=Ctgene-Ctβ-actin, and the results were expressed as 2-ΔCt values. The specific primer sequences are shown in the following table:

[0181]

[0182] 1.9 Data Analysis

[0183] Prism 8 software was used to analyze the experimental data. Unpaired t-test was used for comparison between two groups, and one-way ANOVA was used for comparison between multiple groups. The data were expressed as mean ± standard error (Mean ± SEM), and P < 0.05 was interpreted as statistically significant.

[0184] 2. Experimental results

[0185] 2.1Chrdl1 expression is downregulated in the glomeruli of mice resistant to glomerular basement membrane nephritis

[0186] First, we searched the RNA sequencing and transcriptomic analysis results in the database and found that Chrdl1 was significantly downregulated in the kidneys of mice with renal injury. In order to explore the role of Chrdl1 in the development of anti-glomerular basement membrane nephritis, we injected AAV9-shScramble and AAV9-shChrdl1 viral particles into C57BL / 6J mice via the tail vein, and injected NTS three weeks later to establish an anti-glomerular basement membrane nephritis model. Urine and serum samples were collected on the 3rd, 5th, 7th, and 14th days after injection to detect urine protein and urine creatinine content, and kidney tissue was taken to observe pathological changes and extract RNA. qRT-PCR results showed that compared with the control group, the gene transcription level of Chrdl1 in the kidneys of mice with NTS-induced anti-glomerular basement membrane nephritis was significantly downregulated (P<0.0001, n=10) ( Figure 1 ), HE and PAS results showed that compared with the AAV9-shScramble group, the renal tubular damage of anti-GBM nephritis mice treated with AAV-shChrdl1 was significantly alleviated, and the macrophage infiltration was reduced ( Figure 2 ).

[0187] 2.2 Systemic delivery of AAV9-shChrdl1 alleviates anti-GBM nephritis

[0188] In order to verify that exogenous administration of AAV9-shChrdl1 can be used as a treatment for anti-glomerular basement membrane nephritis, we designed and assembled AAV9-shChrdl1 and injected it into C57BL / 6J mice through the tail vein system for 3 weeks and then 2 weeks of anti-glomerular basement membrane nephritis. Urine and serum samples were collected on the 3rd, 5th, 7th, and 14th days after injection to detect urine protein and urine creatinine content, respectively. The test results showed that compared with the AAV9-shScramble group, the urine protein / creatinine ratio (ACR) of mice in the AAV9-shChrdl1 treatment group was significantly decreased (P<0.01, n=10) ( Figure 4 ); PAS staining results showed that the glomerular damage in the AAV9-shChrdl1 treatment group was milder ( Figure 2); Transmission electron microscopy was used to analyze the ultrastructural changes of glomerular capillary loops between the two groups. The results showed that compared with the AAV9-shScramble group, the podocyte foot processes of the glomerular podocytes in mice treated with AAV9-shChrdl1 were widened, fused, and missing, and the basement membrane was significantly thickened ( Figure 3 ). Immunofluorescence results showed that compared with the CTL group, the protein expression levels of podocyte-related molecules (Podocin, Desmin) in mice treated with AAV9-shChrdl1 decreased ( Figure 5 ). Compared with the AAV9-shScramble group, the transcription levels of Nphs1 and Nphs2 genes, podocyte-related molecules in the kidneys of mice treated with AAV9-shChrdl1, were upregulated, the transcription levels of inflammatory markers (Mcp-1, F4 / 80, Il-1β) were downregulated, and the transcription levels of Id1, Id2, Id3, and Id4 genes, target genes of the pSMAD signaling pathway, were upregulated ( Figure 6 ).

[0189] In summary, knocking down Chrdl1 can significantly reduce the proteinuria level of anti-GBM nephritis, improve the damage of glomerular morphology in anti-GBM nephritis, and improve the dysfunction of podocytes. Therefore, making Chrdl1 into a drug (for example: Chrdl1 knockdown virus particle AAV9-shChrdl1) and administering it in a suitable manner (for example: intravascular injection, intramuscular injection, in situ tissue injection and oral administration) can significantly improve the pathological characteristics of renal injury, and has no side effects, significant therapeutic effects, no complications, and can fundamentally improve and delay the occurrence of anti-GBM nephritis.

[0190] The following are two specific application examples:

[0191] ###Example 1: Study on the preventive effect of Chrdl1 knockdown against glomerular basement membrane nephritis

[0192] Step 1: Mouse model construction

[0193] Wild-type mice were injected with AAV9-shScramble viral particles as a control group.

[0194] For the mouse model with Chrdl1 gene knockdown, Chrdl1 knockdown virus particles AAV9-shChrdl1 can be selectively administered to study the preventive effect of exogenous Chrdl1 against glomerular basement membrane nephritis.

[0195] Administration: intravascular injection or intramuscular injection.

[0196] Dosage and frequency of administration: determined according to the experimental design and mouse body weight.

[0197] Step 2: Establishment of anti-glomerular basement membrane nephritis model

[0198] 1. Anti-glomerular basement membrane nephritis model was established in knockdown mice and control mice.

[0199] Step 3: Observation and Evaluation

[0200] 1. Regularly test the renal function indicators of mice, such as urine protein, urine creatinine, etc.

[0201] 2. Perform histopathological examination to evaluate changes in renal structure and function.

[0202] 3. Analyze the relationship between Chrdl1 expression level and the occurrence and development of anti-glomerular basement membrane nephritis.

[0203] Step 5: Data Analysis

[0204] 1. Statistical analysis of experimental results was performed to compare the differences between the two groups of mice in terms of renal function, histopathology, etc.

[0205] 2. Evaluate the preventive effect of Chrdl1 knockdown against glomerular basement membrane nephritis.

[0206] ###Example 2: Study on the therapeutic effect of Chrdl1 inhibitor against glomerular basement membrane nephritis

[0207] Step 1: Mouse model construction

[0208] 1. The anti-glomerular basement membrane nephritis mouse model was used as the experimental group.

[0209] Step 2: Administer medication

[0210] 1. Give the experimental group mice a Chrdl1 inhibitor, such as a drug that can inhibit Chrdl1 gene expression or Chrdl1 protein activity.

[0211] Administration: oral administration or in situ injection into tissues.

[0212] Dosage and frequency of administration: determined according to the experimental design and mouse body weight.

[0213] Step 3: Observation and Evaluation

[0214] 1. Regularly test the renal function indicators of mice.

[0215] 2. Perform histopathological examination to evaluate changes in renal structure and function.

[0216] 3. Analyze the therapeutic effect of Chrdl1 inhibitors against glomerular basement membrane nephritis.

[0217] Step 4: Data Analysis

[0218] 1. Statistical analysis of experimental results, comparing the differences in renal function, histopathology, etc. of mice before and after administration.

[0219] 2. Evaluate the therapeutic effect of Chrdl1 inhibitors against glomerular basement membrane nephritis, as well as side effects and safety issues.

[0220] It should be noted that the embodiments of the present invention can be implemented by hardware, software, or a combination of software and hardware. The hardware part can be implemented using dedicated logic; the software part can be stored in a memory and executed by an appropriate instruction execution system, such as a microprocessor or dedicated design hardware. It can be understood by a person of ordinary skill in the art that the above-mentioned devices and methods can be implemented using computer executable instructions and / or contained in a processor control code, such as a carrier medium such as a disk, CD or DVD-ROM, a programmable memory such as a read-only memory (firmware), or a data carrier such as an optical or electronic signal carrier. Such code is provided on the carrier medium. The device and its modules of the present invention can be implemented by hardware circuits such as very large-scale integrated circuits or gate arrays, semiconductors such as logic chips, transistors, etc., or programmable hardware devices such as field programmable gate arrays, programmable logic devices, etc., can also be implemented by software executed by various types of processors, and can also be implemented by a combination of the above-mentioned hardware circuits and software, such as firmware.

[0221] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.

Claims

1. A use of Chrdl1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis, characterized in that: The method comprises the following steps: By designing and constructing a mouse model with Chrdl1 knockdown, the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis was studied.

2. The use of Chrdl1 according to claim 1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis, characterized in that: The mouse model simulates the condition of Chrdl1 deficiency, which is helpful to observe and analyze the function of Chrdl1 in anti-glomerular basement membrane nephritis.

3. The use of Chrdl1 according to claim 1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis, characterized in that: The drug is the Chrdl1 knockdown viral particle AAV9-shChrdl1.

4. The use of Chrdl1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis according to claim 3, characterized in that: The administration method of the Chrdl1 knockdown virus particle AAV9-shChrdl1 is intravascular injection, intramuscular injection, in situ tissue injection and oral administration.

5. The use of Chrdl1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis according to claim 1, characterized in that: The drug is a drug that reduces the expression of Chrdl1 gene and / or Chrdl1 protein.

6. The use of Chrdl1 in the preparation of a drug for treating and delaying glomerular basement membrane nephritis according to claim 1, characterized in that: The drug is a drug that reduces the activity of the Chrdl1 protein.

7. A method for studying the relationship between Chrdl1 and the occurrence and development of anti-glomerular basement membrane nephritis, characterized in that: The method comprises the following steps: (1) Wild-type mice were injected with AAV-shscramble virus as a control group; (2) wild-type mice were injected with AAV9-shChrdl1 virus as the experimental group to simulate the condition of reduced Chrdl1 expression; (3) Establish an anti-GBM nephritis model in the above two groups of mice and monitor the course of the disease; (4) Analyze the performance of the Chrdl1 knockdown mouse model during the development of anti-GBM nephritis to study the relationship between Chrdl1 and anti-GBM nephritis.

8. A drug for treating and delaying anti-glomerular basement membrane nephritis, characterized in that: The drug contains the Chrdl1 knockdown virus particle AAV9-shChrdl1, and its working principle is: (1) introducing AAV9-shChrdl1 virus particles containing the Chrdl1 gene into the patient's body by injection or other administration methods; (2) AAV9-shChrdl1 viral particles selectively infect and integrate into kidney cells in patients; (3) In kidney cells, AAV9-shChrdl1 inhibits the expression of the Chrdl1 gene, thereby reducing the level of Chrdl1 protein in kidney cells; (4) Treat and delay anti-glomerular basement membrane nephritis through the biological effects of Chrdl1 protein, such as activating the BMP-SMAD signaling pathway, alleviating renal inflammatory response and improving renal function.

9. A method for using a drug for treating and delaying glomerular basement membrane nephritis, characterized in that: The method comprises the following steps: (1) Wild-type mice were used as the control group, and a mouse model with Chrdl1 gene knockdown was constructed as the experimental group; (2) Establish anti-GBM nephritis models in two groups of mice and monitor the course of the disease; (3) For the mouse model with knockdown of Chrdl1 gene, the Chrdl1 knockdown virus particles AAV9-shChrdl1 were administered by intravascular injection or intramuscular injection. The dosage and frequency of administration were determined according to the experimental design and mouse weight. (4) Regularly test the renal function indicators of mice, such as urine protein and urine creatinine, and perform histopathological examinations to evaluate changes in renal structure and function; (5) The experimental results were statistically analyzed and the differences in renal function, histopathology, etc. between the two groups of mice were compared to evaluate the therapeutic effect of knocking down Chrdl1 against glomerular basement membrane nephritis.

10. A method for using a drug for treating anti-glomerular basement membrane nephritis, characterized in that: The method comprises the following steps: (1) Use an established mouse model of renal injury as the experimental group; (2) Giving the experimental group mice a Chrdl1 inhibitor that can reduce Chrdl1 gene expression or Chrdl1 protein activity, with oral administration or in situ tissue injection. The dosage and frequency of administration are determined according to the experimental design and mouse weight; (3) Regularly test the renal function indicators of mice and perform histopathological examinations to evaluate changes in renal structure and function; (4) Statistically analyze the experimental results and compare the differences in renal function, histopathology, etc. between mice before and after administration to evaluate the therapeutic effect of Chrdl1 inhibitors against glomerular basement membrane nephritis and consider its side effects and safety issues.